# Eli Lilly releases promising early-stage data on ADC for ovarian cancer — retained record

> Retained news record from news:seeking-alpha.

Canonical: https://highsignal.app/data/records/eea94327ec52c008

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:seeking-alpha)  published 2026-10-24 14:10 ingested 2026-10-24 14:50

[original source ↗](https://seekingalpha.com/news/4656928-eli-lilly-releases-promising-early-stage-data-adc-ovarian-cancer?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news)

## retained text



```
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in

Eli Lilly releases promising early-stage data on ADC for ovarian cancer

Oct 24, 2026, 10:10 AM ETEli Lilly and Company (LLY) StockBy: Jonathan Block, SA News Editor

Phase 1 data on Eli Lilly's (LLY) sofetabart mipitecan (Sofe-M) found that the antibody-drug conjugate plus Avastin (bevacizumab) led to high objective response and disease control rates in individuals with platinum-sensitive ovarian cancer.

Results showed that the combo led to

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Recommended For You
```



document fetched 2026-10-24 14:50 · canonical https://seekingalpha.com/news/4656928-eli-lilly-releases-promising-early-stage-data-adc-ovarian-cancer?feed_item_type=news